Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MLD-55 (escitalopram) in Japanese adolescents with depression
jRCT2080224520Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and persistent depressive disorder (PDD) comparing MLD-55 (escitalopram) with Placebo (2 arms). Primary endpoint: Time to relapse. Started Jan 2019; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on jRCT2080224520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224520.